Get the Stockscreener App
543.19
1.48%
7.90
Pre-market:
543.20
0.010
+0.00%
Overview
News
Price History
Option Chain
Financials
Why TMO Down?
Discussions
Forecast
Stock Split
Dividend History
Thermo Fisher Scientific Inc stock is traded at $543.19, with a volume of 1.90M.
It is up +1.48% in the last 24 hours and up +14.93% over the past month.
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year-end 2025 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).
See More
Previous Close:
$535.29
Open:
$536.25
24h Volume:
1.90M
Relative Volume:
0.83
Market Cap:
$201.86B
Revenue:
$45.20B
Net Income/Loss:
$6.87B
P/E Ratio:
29.86
EPS:
18.1888
Net Cash Flow:
$6.75B
1W Performance:
+3.52%
1M Performance:
+14.93%
6M Performance:
-12.21%
1Y Performance:
+30.48%
1-Day Range:
$532.01
$544.45
1-Week Range:
$521.77
$544.45
52-Week Range:
$403.36
$643.99
Thermo Fisher Scientific Inc Stock (TMO) Company Profile
Name
Thermo Fisher Scientific Inc
Sector
Industry
Phone
(781) 622-1000
Address
168 THIRD AVENUE, WALTHAM, MA
Compare TMO vs DHR, IDXX, NTRA, A
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TMO
Thermo Fisher Scientific Inc
|
543.19 | 201.86B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
205.01 | 145.10B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
576.07 | 45.44B | 4.45B | 1.10B | 1.06B | 13.59 |
NTRA
Natera Inc
|
269.83 | 38.64B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
136.10 | 38.44B | 7.23B | 1.41B | 1.09B | 4.979 |
Thermo Fisher Scientific Inc Stock (TMO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-27-26 | Initiated | DZ Bank | Buy |
| Dec-11-25 | Upgrade | Citigroup | Neutral → Buy |
| Dec-09-25 | Initiated | Goldman | Buy |
| Dec-08-25 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Dec-02-25 | Resumed | Morgan Stanley | Overweight |
| Dec-01-25 | Upgrade | HSBC Securities | Hold → Buy |
| Sep-11-25 | Upgrade | Barclays | Equal Weight → Overweight |
| Aug-19-25 | Initiated | William Blair | Outperform |
| Jul-24-25 | Downgrade | HSBC Securities | Buy → Hold |
| Jul-11-25 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Jul-09-25 | Downgrade | UBS | Buy → Neutral |
| Jan-10-25 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Dec-23-24 | Initiated | Scotiabank | Sector Perform |
| Oct-14-24 | Initiated | Redburn Atlantic | Buy |
| Oct-01-24 | Initiated | Stephens | Overweight |
| Aug-28-24 | Initiated | Wells Fargo | Overweight |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Mar-18-24 | Resumed | Citigroup | Neutral |
| Jan-24-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Jan-08-24 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Dec-18-23 | Initiated | HSBC Securities | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Oct-26-23 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Oct-25-23 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Sep-06-23 | Resumed | Citigroup | Buy |
| Jul-19-23 | Initiated | Raymond James | Outperform |
| Jul-19-23 | Reiterated | Robert W. Baird | Outperform |
| Jul-13-23 | Upgrade | Credit Suisse | Neutral → Outperform |
| Apr-04-23 | Reiterated | Barclays | Overweight |
| Dec-14-22 | Initiated | Deutsche Bank | Buy |
| Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
| Oct-27-22 | Downgrade | The Benchmark Company | Buy → Hold |
| Aug-25-22 | Initiated | Credit Suisse | Neutral |
| Apr-25-22 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| Jan-26-22 | Resumed | Barclays | Overweight |
| Oct-20-21 | Upgrade | Citigroup | Neutral → Buy |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Jul-16-21 | Initiated | The Benchmark Company | Buy |
| Mar-18-21 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Mar-03-21 | Initiated | Barclays | Overweight |
| Jan-08-21 | Upgrade | Credit Suisse | Neutral → Outperform |
| Dec-16-20 | Downgrade | Citigroup | Buy → Neutral |
| Dec-02-20 | Initiated | Goldman | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Sep-30-20 | Initiated | Atlantic Equities | Overweight |
| Sep-14-20 | Initiated | Morgan Stanley | Overweight |
| Aug-20-20 | Resumed | JP Morgan | Overweight |
| Jul-15-20 | Upgrade | Cleveland Research | Neutral → Buy |
| Jul-07-20 | Reiterated | Needham | Buy |
| Apr-23-20 | Reiterated | Needham | Buy |
| Jan-31-20 | Reiterated | Needham | Buy |
| Jan-22-20 | Initiated | Credit Suisse | Neutral |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Nov-15-19 | Initiated | Stifel | Buy |
| Jul-25-19 | Reiterated | Needham | Buy |
| Jul-16-19 | Downgrade | Needham | Strong Buy → Buy |
| May-30-19 | Initiated | Wolfe Research | Outperform |
| May-23-19 | Reiterated | Needham | Strong Buy |
| Apr-22-19 | Reiterated | Needham | Strong Buy |
| Apr-16-19 | Reiterated | BofA/Merrill | Buy |
View All
Thermo Fisher Scientific Inc Stock (TMO) Latest News
Thermo Fisher Scientific Inc. stock rises Thursday, outperforms market - MarketWatch
Precision Trading with Thermo Fisher Scientific Inc (TMO) Risk Zones - Stock Traders Daily
Fund Update: 148,999 THERMO FISHER SCIENTIFIC (TMO) shares added to Canoe Financial LP portfolio - Quiver Quantitative
Devyser announced the launch of next generation chimerism analysis solution, strengthening its offering in post-transplant monitoring - TradingView
Thermo Fisher stock reflects a steady life science growth story - Ad Hoc News
Thermo Fisher Set to Report Q2 Earnings: What's in the Cards? - Yahoo Finance
Global Clinical Trials Market to Reach $176.32 Billion by 2030 as AI and Decentralized Research Accelerate Growth - GlobeNewswire Inc.
Thermo Fisher Scientific Inc. stock rises Tuesday, outperforms market - MarketWatch
World Syringes for Thermo ScientificMarket Analysis, Forecast, Size, Trends and Insights - IndexBox
Intuitive Surgical Pre-Q2 Analysis: Buy, Hold or Sell the Stock Now? - TradingView
The Invitrogen EVOS M7000 Imaging SystemThermo Fisher bets on automated cell imaging - Ad Hoc News
Thermo Fisher Scientific lays off nearly 70 Wisconsin employees - AOL.com
Thermo Fisher Stock Looks Cheap Next to Its Own Forecast. Here’s the Math. - TIKR.com
Thermo Fisher Scientific (TMO) Valuation Insights: DCF Analysis Suggests $478 Per Share - GuruFocus
Baird Adjusts Price Target on Thermo Fisher Scientific to $652 From $639, Maintains Outperform Rating - marketscreener.com
Thermo Fisher Scientific (TMO) 47th Annual Raymond James Institutional Investor Conference summary - Quartr
Thermo Fisher Scientific (TMO) Q1 2026 earnings summary - Quartr
Thermo Fisher stock holds steady as investors await catalysts - ad-hoc-news.de
Thermo Fisher Looks To Block Former Exec's Move To Fortrea - Law360
symbol__ Stock Quote Price and Forecast - CNN
Thermo Fisher stock holds steady as investors focus on life-science demand - ad-hoc-news.de
Thermo Fisher Scientific (TMO) Announces Consistent Quarterly Di - GuruFocus
Thermo Fisher Scientific Keeps Quarterly Dividend at $0.47 per Share, Payable Oct. 15 to Holders of Record Sept. 15 - Moomoo
Thermo Fisher declares $0.47 quarterly dividend By Investing.com - Investing.com Nigeria
Press Release: Thermo Fisher Scientific Announces Quarterly Dividend - 富途牛牛
Thermo Fisher Scientific to lay off 69 - In Business Madison
Thermo Fisher Q2 Preview: Buy Before The Recovery (NYSE:TMO) - Seeking Alpha
Thermo Fisher Scientific strengthens its life science platform as demand for lab tools stays resilie - AD HOC NEWS
Thermo Fisher Sci. steady after recent updates. Investors focus on healthcare demand - Ad-hoc-news.de
Thermo Fisher Scientific Inc. stock falls Wednesday, underperforms market - MarketWatch
Thermo Fisher expands its scientific footprint as investors assess long-term growth - Ad-hoc-news.de
Thermo Fisher Scientific Launches GENESYS G5 UV-Visible Spectrophotometer Series - Food Safety Magazine
Cell Culture Media Market worth $12.9 billion by 2033: Biologics Manufacturing and Cell Therapy Expansion Accelerate Growth for Avantor, Thermo Fisher Scientific, and Lonza Group AG - PR Newswire
Thermo Fisher's Patheon becomes exclusive third-party CDMO for KinetiSol technology - Manufacturing Chemist
Thermo Fisher Scientific (TMO) Q3 2025 earnings summary - Quartr
Thermo Fisher (TMO) Wins FBI Approval For Rapid DNA Tool In Crime Investigations - Yahoo Finance
Thermo Fisher Scientific Expands Orbitrap Innovation Across Research, Biopharma and Applied Testing at ASMS 2026 - AOL.com
Thermo Fisher Scientific Launches New Quality Assurance Software - Clinical Lab Products
Thermo Fisher Scientific Receives First FBI Approval for Rapid DNA Crime Scene Profiles Eligible for National CODIS Searches - AOL.com
TMO Maintained by Evercore ISI Group -- Price Target Lowered to $570 - GuruFocus
Thermo Fisher Scientific Inc. stock falls Monday, underperforms market - MarketWatch
Evercore Maintains Thermo Fisher Scientific(TMO.US) With Buy Rating, Cuts Target Price to $570 - Moomoo
Evercore ISI Adjusts Price Target on Thermo Fisher Scientific to $570 From $575 - marketscreener.com
Thermo Fisher Scientific Inc (TMO) Stock Analysis: Evaluating The 13.91% Potential Upside - DirectorsTalk Interviews
Shapiro Administration Highlights the Need for Funding to Grow Pennsylvania’s Innovation Economy During Visit to Thermo Fisher Scientific in Dauphin County - PA Department of Community & Economic Development (.gov)
Thermo Fisher launches LabLink 360 software to streamline QC review workflows - Select Science
Kavaljer Investmentbolagsfond June 2026 – Thermo Fisher and Siemens New Holdings - marketscreener.com
Arcturus Therapeutics Holdings Inc. And Thermo Fisher Scientific Inc. Announce Strategic Collaboration To Advance ARCT-032 For Cystic Fibrosis - marketscreener.com
Arcturus Therapeutics Announces Strategic Collaboration With Thermo Fisher Scientific - TradingView
Thermo Fisher to back Arcturus (NASDAQ: ARCT) ARCT-032 Phase 3 and manufacturing - Stock Titan
Arcturus Therapeutics Announces Strategic Collaboration with Thermo Fisher Scientific to Advance ARCT-032 for Cystic Fibrosis - Business Wire
Thermo Fisher Scientific Inc Stock (TMO) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.10%
2.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):